{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T15:25:04Z","timestamp":1786116304120,"version":"build-2736575974"},"reference-count":51,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T00:00:00Z","timestamp":1779062400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T00:00:00Z","timestamp":1779062400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100022274","name":"Daiichi Sankyo Europe","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100022274","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Thromb Thrombolysis"],"DOI":"10.1007\/s11239-026-03269-5","type":"journal-article","created":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T06:31:13Z","timestamp":1779085873000},"page":"1362-1374","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Edoxaban for atrial fibrillation in patients with atherosclerotic disease in daily clinical practice"],"prefix":"10.1007","volume":"59","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1392-8193","authenticated-orcid":false,"given":"Tim A.C.","family":"de Vries","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8122-7017","authenticated-orcid":false,"given":"Joris R.","family":"de Groot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8965-0664","authenticated-orcid":false,"given":"Ron","family":"Pisters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2373-9858","authenticated-orcid":false,"given":"Martin E.W.","family":"Hemels","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5471-3132","authenticated-orcid":false,"given":"Joris J.","family":"Komen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-4464-1023","authenticated-orcid":false,"given":"R\u00fcdiger","family":"Smolnik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva-Maria","family":"Fronk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1477-9153","authenticated-orcid":false,"given":"Jan","family":"Steffel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Weiss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carlo","family":"de Asmundis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paulus","family":"Kirchhof","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1637-574X","authenticated-orcid":false,"given":"Raffaele","family":"De Caterina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,18]]},"reference":[{"issue":"1","key":"3269_CR1","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.advms.2017.06.005","volume":"63","author":"E Michniewicz","year":"2018","unstructured":"Michniewicz E, Mlodawska E, Lopatowska P, Tomaszuk-Kazberuk A, Malyszko J (2018) Patients with atrial fibrillation and coronary artery disease - double trouble. Adv Med Sci 63(1):30\u201335. https:\/\/doi.org\/10.1016\/j.advms.2017.06.005","journal-title":"Adv Med Sci"},{"issue":"5","key":"3269_CR2","doi-asserted-by":"publisher","first-page":"855","DOI":"10.1016\/j.ahj.2008.06.029","volume":"156","author":"S Goto","year":"2008","unstructured":"Goto S, Bhatt DL, R\u00f6ther J et al (2008) Prevalence, clinical profile, and cardiovascular outcomes of atrial fibrillation patients with atherothrombosis. Am Heart J 156(5):855\u2013863, 863.e852. https:\/\/doi.org\/10.1016\/j.ahj.2008.06.029","journal-title":"Am Heart J"},{"key":"3269_CR3","doi-asserted-by":"publisher","unstructured":"Cho Min S, Kang D-Y, Ahn J-M et al (2024) Edoxaban Antithrombotic Therapy for Atrial Fibrillation and Stable Coronary Artery Disease. N Engl J Med 0(0). https:\/\/doi.org\/10.1056\/NEJMoa2407362","DOI":"10.1056\/NEJMoa2407362"},{"issue":"10206","key":"3269_CR4","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1016\/s0140-6736(19)31872-0","volume":"394","author":"P Vranckx","year":"2019","unstructured":"Vranckx P, Valgimigli M, Eckardt L et al (2019) Edoxaban-based versus vitamin K antagonist-based antithrombotic regimen after successful coronary stenting in patients with atrial fibrillation (ENTRUST-AF PCI): a randomised, open-label, phase 3b trial. Lancet 394(10206):1335\u20131343. https:\/\/doi.org\/10.1016\/s0140-6736(19)31872-0","journal-title":"Lancet"},{"key":"3269_CR5","doi-asserted-by":"publisher","DOI":"10.1155\/2022\/5905022","volume":"2022","author":"D Fukamachi","year":"2022","unstructured":"Fukamachi D, Okumura Y, Matsumoto N et al (2022) Edoxaban monotherapy in nonvalvular atrial fibrillation patients with coronary artery disease. J Interv Cardiol 2022:5905022. https:\/\/doi.org\/10.1155\/2022\/5905022","journal-title":"J Interv Cardiol"},{"issue":"6","key":"3269_CR6","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1177\/2048872618796990","volume":"8","author":"TA Zelniker","year":"2019","unstructured":"Zelniker TA, Ruff CT, Antman EM, Giugliano RP (2019) The efficacy and safety of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation and coronary artery disease: a meta-analysis of randomized trials. Eur Heart J Acute Cardiovasc Care 8(6):554\u2013561. https:\/\/doi.org\/10.1177\/2048872618796990","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"issue":"7","key":"3269_CR7","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1093\/ehjcvp\/pvab089","volume":"8","author":"MP Bonaca","year":"2022","unstructured":"Bonaca MP, Antman EM, Cunningham JW et al (2022) Ischaemic and bleeding risk in atrial fibrillation with and without peripheral artery disease and efficacy and safety of full- and half-dose edoxaban vs. warfarin: insights from ENGAGE AF-TIMI 48. Eur Heart J Cardiovasc Pharmacother 8(7):695\u2013706. https:\/\/doi.org\/10.1093\/ehjcvp\/pvab089","journal-title":"Eur Heart J Cardiovasc Pharmacother"},{"issue":"2","key":"3269_CR8","doi-asserted-by":"publisher","first-page":"176","DOI":"10.1177\/2048872618790561","volume":"8","author":"TA Zelniker","year":"2019","unstructured":"Zelniker TA, Ruff CT, Wiviott SD et al (2019) Edoxaban in atrial fibrillation patients with established coronary artery disease: insights from ENGAGE AF-TIMI 48. Eur Heart J Acute Cardiovasc Care 8(2):176\u2013185. https:\/\/doi.org\/10.1177\/2048872618790561","journal-title":"Eur Heart J Acute Cardiovasc Care"},{"issue":"2","key":"3269_CR9","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1378\/chest.09-1584","volume":"137","author":"GY Lip","year":"2010","unstructured":"Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ (2010) Refining clinical risk stratification for predicting stroke and thromboembolism in atrial fibrillation using a novel risk factor-based approach: the euro heart survey on atrial fibrillation. Chest 137(2):263\u2013272. https:\/\/doi.org\/10.1378\/chest.09-1584","journal-title":"Chest"},{"issue":"22","key":"3269_CR10","doi-asserted-by":"publisher","first-page":"2093","DOI":"10.1056\/NEJMoa1310907","volume":"369","author":"RP Giugliano","year":"2013","unstructured":"Giugliano RP, Ruff CT, Braunwald E et al (2013) Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 369(22):2093\u20132104. https:\/\/doi.org\/10.1056\/NEJMoa1310907","journal-title":"N Engl J Med"},{"issue":"2","key":"3269_CR11","doi-asserted-by":"publisher","first-page":"97","DOI":"10.2459\/jcm.0000000000000737","volume":"20","author":"R De Caterina","year":"2019","unstructured":"De Caterina R, Kelly P, Monteiro P et al (2019) Design and rationale of the Edoxaban Treatment in routiNe clinical prActice for patients with Atrial Fibrillation in Europe (ETNA-AF-Europe) study. J Cardiovasc Med (Hagerstown) 20(2):97\u2013104. https:\/\/doi.org\/10.2459\/jcm.0000000000000737","journal-title":"J Cardiovasc Med (Hagerstown)"},{"issue":"4","key":"3269_CR12","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/j.jclinepi.2007.11.008","volume":"61","author":"E von Elm","year":"2008","unstructured":"von Elm E, Altman DG, Egger M et al (2008) The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol 61(4):344\u2013349. https:\/\/doi.org\/10.1016\/j.jclinepi.2007.11.008","journal-title":"J Clin Epidemiol"},{"key":"3269_CR13","unstructured":"European Medicines Agency Lixiana: EPAR-Product Information. Committee for Medicinal Products for Human Use (CHMP); Jul 3, 2015. URL: https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/lixiana-epar-product-information_en.pdf"},{"issue":"4","key":"3269_CR14","doi-asserted-by":"publisher","first-page":"692","DOI":"10.1111\/j.1538-7836.2005.01204.x","volume":"3","author":"S Schulman","year":"2005","unstructured":"Schulman S, Kearon C (2005) Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 3(4):692\u2013694. https:\/\/doi.org\/10.1111\/j.1538-7836.2005.01204.x","journal-title":"J Thromb Haemost"},{"issue":"7","key":"3269_CR15","doi-asserted-by":"publisher","first-page":"1941","DOI":"10.1007\/s11739-024-03701-9","volume":"19","author":"E Soler-Espejo","year":"2024","unstructured":"Soler-Espejo E, Rivera-Caravaca JM, Bru-C\u00e1novas JD et al (2024) Patients with atrial fibrillation and common exclusion criteria from clinical trials are at high risk of clinical events: the Murcia AF project II (MAFP-II) cohort study. Intern Emerg Med 19(7):1941\u20131948. https:\/\/doi.org\/10.1007\/s11739-024-03701-9","journal-title":"Intern Emerg Med"},{"key":"3269_CR16","doi-asserted-by":"publisher","first-page":"ehae176","DOI":"10.1093\/eurheartj\/ehae176","volume":"2024","author":"IC Van Gelder","year":"2024","unstructured":"Van Gelder IC, Rienstra M, Bunting KV et al (2024) ESC Guidelines for the management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): Developed by the task force for the management of atrial fibrillation of the European Society of Cardiology (ESC), with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Endorsed by the European Stroke Organisation (ESO). Eur Heart J 2024:ehae176. https:\/\/doi.org\/10.1093\/eurheartj\/ehae176","journal-title":"Eur Heart J"},{"key":"3269_CR17","doi-asserted-by":"publisher","unstructured":"Hindricks G, Potpara T, Dagres N et al (2020) ,. ESC Guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association for Cardio-Thoracic Surgery (EACTS): The Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. Eur Heart J 2021;42(5):373\u2013498. https:\/\/doi.org\/10.1093\/eurheartj\/ehaa612.","DOI":"10.1093\/eurheartj\/ehaa612"},{"issue":"38","key":"3269_CR18","doi-asserted-by":"publisher","first-page":"2893","DOI":"10.1093\/eurheartj\/ehw210","volume":"37","author":"P Kirchhof","year":"2016","unstructured":"Kirchhof P, Benussi S, Kotecha D et al (2016) 2016 ESC guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur Heart J 37(38):2893\u20132962. https:\/\/doi.org\/10.1093\/eurheartj\/ehw210","journal-title":"Eur Heart J"},{"issue":"11","key":"3269_CR19","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1002\/pds.5650","volume":"32","author":"JJ Komen","year":"2023","unstructured":"Komen JJ, Hunt NB, Potteg\u00e5rd A et al (2023) Heterogeneity after harmonisation: a retrospective cohort study of bleeding and stroke risk after the introduction of direct oral anticoagulants in four Western European countries. Pharmacoepidemiol Drug Saf 32(11):1223\u20131232. https:\/\/doi.org\/10.1002\/pds.5650","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"9","key":"3269_CR20","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1056\/NEJMoa1007432","volume":"364","author":"SJ Connolly","year":"2011","unstructured":"Connolly SJ, Eikelboom J, Joyner C et al (2011) Apixaban in patients with atrial fibrillation. N Engl J Med 364(9):806\u2013817. https:\/\/doi.org\/10.1056\/NEJMoa1007432","journal-title":"N Engl J Med"},{"issue":"11","key":"3269_CR21","doi-asserted-by":"publisher","first-page":"981","DOI":"10.1056\/NEJMoa1107039","volume":"365","author":"CB Granger","year":"2011","unstructured":"Granger CB, Alexander JH, McMurray JJ et al (2011) Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 365(11):981\u2013992. https:\/\/doi.org\/10.1056\/NEJMoa1107039","journal-title":"N Engl J Med"},{"issue":"1","key":"3269_CR22","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa2407105","volume":"392","author":"JP Piccini","year":"2025","unstructured":"Piccini JP, Patel MR, Steffel J et al (2025) Asundexian versus apixaban in patients with atrial fibrillation. N Engl J Med 392(1):23\u201332. https:\/\/doi.org\/10.1056\/NEJMoa2407105","journal-title":"N Engl J Med"},{"issue":"24","key":"3269_CR23","doi-asserted-by":"publisher","first-page":"3078","DOI":"10.1093\/eurheartj\/ehs318","volume":"33","author":"S Cassese","year":"2012","unstructured":"Cassese S, Byrne RA, Tada T, King LA, Kastrati A (2012) Clinical impact of extended dual antiplatelet therapy after percutaneous coronary interventions in the drug-eluting stent era: a meta-analysis of randomized trials. Eur Heart J 33(24):3078\u20133087. https:\/\/doi.org\/10.1093\/eurheartj\/ehs318","journal-title":"Eur Heart J"},{"key":"3269_CR24","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2507532","author":"G Lemesle","year":"2025","unstructured":"Lemesle G, Didier R, Steg PG et al (2025) Aspirin in patients with chronic coronary syndrome receiving oral anticoagulation. N Engl J Med. https:\/\/doi.org\/10.1056\/NEJMoa2507532","journal-title":"N Engl J Med"},{"issue":"10","key":"3269_CR25","doi-asserted-by":"publisher","first-page":"1612","DOI":"10.1093\/europace\/euab065","volume":"23","author":"J Steffel","year":"2021","unstructured":"Steffel J, Collins R, Antz M et al (2021) 2021 European Heart Rhythm Association practical guide on the use of non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation. Europace 23(10):1612\u20131676. https:\/\/doi.org\/10.1093\/europace\/euab065","journal-title":"Europace"},{"issue":"08","key":"3269_CR26","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1055\/a-1450-8178","volume":"121","author":"J Douxfils","year":"2021","unstructured":"Douxfils J, Adcock DM, Bates SM et al (2021) 2021 update of the International Council for Standardization in Haematology recommendations for laboratory measurement of direct oral anticoagulants. Thromb Haemost 121(08):1008\u20131020. https:\/\/doi.org\/10.1055\/a-1450-8178","journal-title":"Thromb Haemost"},{"issue":"2","key":"3269_CR27","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1055\/a-1113-0655","volume":"40","author":"T Moner-Banet","year":"2020","unstructured":"Moner-Banet T, Alberio L, Bart PA (2020) Does one dose really fit all? On the monitoring of direct oral anticoagulants: a review of the literature. Hamostaseologie 40(2):184\u2013200. https:\/\/doi.org\/10.1055\/a-1113-0655","journal-title":"Hamostaseologie"},{"issue":"9","key":"3269_CR28","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.1016\/j.jacc.2020.12.053","volume":"77","author":"J Steffel","year":"2021","unstructured":"Steffel J, Ruff CT, Yin O et al (2021) Randomized, double-blind comparison of half-dose versus full-dose edoxaban in 14,014 patients with atrial fibrillation. J Am Coll Cardiol 77(9):1197\u20131207. https:\/\/doi.org\/10.1016\/j.jacc.2020.12.053","journal-title":"J Am Coll Cardiol"},{"issue":"9","key":"3269_CR29","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1001\/jamacardio.2024.1793","volume":"9","author":"A Zimerman","year":"2024","unstructured":"Zimerman A, Braunwald E, Steffel J et al (2024) Dose reduction of edoxaban in patients 80 years and older with atrial fibrillation: post hoc analysis of the ENGAGE AF-TIMI 48 randomized clinical trial. JAMA Cardiol 9(9):817\u2013825. https:\/\/doi.org\/10.1001\/jamacardio.2024.1793","journal-title":"JAMA Cardiol"},{"issue":"18","key":"3269_CR30","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1161\/circulationaha.118.033933","volume":"138","author":"OQP Yin","year":"2018","unstructured":"Yin OQP, Antman EM, Braunwald E et al (2018) Linking endogenous factor Xa activity, a biologically relevant pharmacodynamic marker, to edoxaban plasma concentrations and clinical outcomes in the ENGAGE AF-TIMI 48 trial. Circulation 138(18):1963\u20131973. https:\/\/doi.org\/10.1161\/circulationaha.118.033933","journal-title":"Circulation"},{"key":"3269_CR31","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtha.2025.06.031","author":"C Godino","year":"2025","unstructured":"Godino C, Mazza R, Gaspardone C et al (2025) Plasma levels measurement of the 4 direct oral anticoagulants in patients with atrial fibrillation at the time of acute thromboembolic and bleeding events. J Thromb Haemost. https:\/\/doi.org\/10.1016\/j.jtha.2025.06.031","journal-title":"J Thromb Haemost"},{"issue":"18","key":"3269_CR32","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1056\/NEJMoa2012883","volume":"383","author":"K Okumura","year":"2020","unstructured":"Okumura K, Akao M, Yoshida T et al (2020) Low-dose edoxaban in very elderly patients with atrial fibrillation. N Engl J Med 383(18):1735\u20131745. https:\/\/doi.org\/10.1056\/NEJMoa2012883","journal-title":"N Engl J Med"},{"key":"3269_CR33","doi-asserted-by":"publisher","DOI":"10.1161\/circulationaha.123.066485","author":"LPT Joosten","year":"2023","unstructured":"Joosten LPT, van Doorn S, van de Ven PM et al (2023) Safety of Switching from a Vitamin K Antagonist to a Non-Vitamin K Antagonist Oral Anticoagulant in Frail Older Patients with Atrial Fibrillation: Results of the FRAIL-AF Randomized Controlled Trial. Circulation. https:\/\/doi.org\/10.1161\/circulationaha.123.066485","journal-title":"Circulation"},{"issue":"6","key":"3269_CR34","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1681\/asn.2020111566","volume":"32","author":"AS De Vriese","year":"2021","unstructured":"De Vriese AS, Caluw\u00e9 R, Van Der Meersch H, De Boeck K, De Bacquer D (2021) Safety and efficacy of vitamin K antagonists versus rivaroxaban in hemodialysis patients with atrial fibrillation: a multicenter randomized controlled trial. J Am Soc Nephrol 32(6):1474\u20131483. https:\/\/doi.org\/10.1681\/asn.2020111566","journal-title":"J Am Soc Nephrol"},{"issue":"23","key":"3269_CR35","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1161\/circulationaha.121.054990","volume":"146","author":"SD Pokorney","year":"2022","unstructured":"Pokorney SD, Chertow GM, Al-Khalidi HR et al (2022) Apixaban for patients with atrial fibrillation on hemodialysis: a multicenter randomized controlled trial. Circulation 146(23):1735\u20131745. https:\/\/doi.org\/10.1161\/circulationaha.121.054990","journal-title":"Circulation"},{"issue":"10","key":"3269_CR36","doi-asserted-by":"publisher","first-page":"922","DOI":"10.1001\/jamacardio.2024.2335","volume":"9","author":"X Freixa","year":"2024","unstructured":"Freixa X, Cruz-Gonz\u00e1lez I, Cepas-Guill\u00e9n P et al (2024) Low-dose direct oral anticoagulation vs dual antiplatelet therapy after left atrial appendage occlusion: the ADALA randomized clinical trial. JAMA Cardiol 9(10):922\u2013926. https:\/\/doi.org\/10.1001\/jamacardio.2024.2335","journal-title":"JAMA Cardiol"},{"issue":"12","key":"3269_CR37","doi-asserted-by":"publisher","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","volume":"361","author":"SJ Connolly","year":"2009","unstructured":"Connolly SJ, Ezekowitz MD, Yusuf S et al (2009) Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 361(12):1139\u20131151. https:\/\/doi.org\/10.1056\/NEJMoa0905561","journal-title":"N Engl J Med"},{"issue":"4","key":"3269_CR38","doi-asserted-by":"publisher","first-page":"321","DOI":"10.1016\/j.jacc.2013.07.104","volume":"63","author":"PA Reilly","year":"2014","unstructured":"Reilly PA, Lehr T, Haertter S et al (2014) The effect of dabigatran plasma concentrations and patient characteristics on the frequency of ischemic stroke and major bleeding in atrial fibrillation patients: the RE-LY Trial (Randomized Evaluation of Long-Term Anticoagulation Therapy). J Am Coll Cardiol 63(4):321\u2013328. https:\/\/doi.org\/10.1016\/j.jacc.2013.07.104","journal-title":"J Am Coll Cardiol"},{"issue":"10","key":"3269_CR39","doi-asserted-by":"publisher","first-page":"2983","DOI":"10.1161\/strokeaha.114.005599","volume":"45","author":"CH Yoon","year":"2014","unstructured":"Yoon CH, Park YK, Kim SJ et al (2014) Eligibility and preference of new oral anticoagulants in patients with atrial fibrillation: comparison between patients with versus without stroke. Stroke 45(10):2983\u20132988. https:\/\/doi.org\/10.1161\/strokeaha.114.005599","journal-title":"Stroke"},{"issue":"2","key":"3269_CR40","doi-asserted-by":"publisher","first-page":"e139","DOI":"10.1055\/s-0037-1613679","volume":"1","author":"VC Bhagirath","year":"2017","unstructured":"Bhagirath VC, Eikelboom JW, Hirsh J et al (2017) Apixaban-calibrated anti-FXa activity in relation to outcome events and clinical characteristics in patients with atrial fibrillation: results from the AVERROES trial. TH Open 1(2):e139\u2013e145. https:\/\/doi.org\/10.1055\/s-0037-1613679","journal-title":"TH Open"},{"issue":"16","key":"3269_CR41","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1056\/NEJMoa1708454","volume":"377","author":"CP Cannon","year":"2017","unstructured":"Cannon CP, Bhatt DL, Oldgren J et al (2017) Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation. N Engl J Med 377(16):1513\u20131524. https:\/\/doi.org\/10.1056\/NEJMoa1708454","journal-title":"N Engl J Med"},{"key":"3269_CR42","unstructured":"Rose M, Beasley BN, Center For Drug Evaluation And Research Application Number : 202155Orig1s000 Medical Review(s). US Food and Drug Administration. URL: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2012\/202155Orig1s000MedR.pdf [Accessed November 21, 2021]"},{"issue":"9984","key":"3269_CR43","doi-asserted-by":"publisher","first-page":"2288","DOI":"10.1016\/S0140-6736(14)61943-7","volume":"385","author":"CT Ruff","year":"2015","unstructured":"Ruff CT, Giugliano RP, Braunwald E et al (2015) Association between edoxaban dose, concentration, anti-Factor Xa activity, and outcomes: an analysis of data from the randomised, double-blind ENGAGE AF-TIMI 48 trial. Lancet 385(9984):2288\u20132295. https:\/\/doi.org\/10.1016\/S0140-6736(14)61943-7","journal-title":"Lancet"},{"issue":"1","key":"3269_CR44","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1007\/s11239-020-02077-9","volume":"50","author":"L Zhang","year":"2020","unstructured":"Zhang L, Yan X, Fox KAA et al (2020) Associations between model-predicted rivaroxaban exposure and patient characteristics and efficacy and safety outcomes in patients with non-valvular atrial fibrillation. J Thromb Thrombolysis 50(1):20\u201329. https:\/\/doi.org\/10.1007\/s11239-020-02077-9","journal-title":"J Thromb Thrombolysis"},{"issue":"12","key":"3269_CR45","doi-asserted-by":"publisher","first-page":"2933","DOI":"10.1161\/STROKEAHA.118.020232","volume":"49","author":"GYH Lip","year":"2018","unstructured":"Lip GYH, Keshishian A, Li X et al (2018) Effectiveness and safety of oral anticoagulants among nonvalvular atrial fibrillation patients. Stroke 49(12):2933\u20132944. https:\/\/doi.org\/10.1161\/STROKEAHA.118.020232","journal-title":"Stroke"},{"issue":"5","key":"3269_CR46","doi-asserted-by":"publisher","first-page":"596","DOI":"10.1016\/j.amjmed.2018.12.023","volume":"132","author":"DJ Graham","year":"2019","unstructured":"Graham DJ, Baro E, Zhang R et al (2019) Comparative stroke, bleeding, and mortality risks in older Medicare patients treated with oral anticoagulants for nonvalvular atrial fibrillation. Am J Med 132(5):596-604.e511. https:\/\/doi.org\/10.1016\/j.amjmed.2018.12.023","journal-title":"Am J Med"},{"key":"3269_CR47","doi-asserted-by":"publisher","unstructured":"Higa M, Morimoto T, Ikeda M, Ueda S (2025) Real-World Outcomes of Patients With Non-Valvular Atrial Fibrillation on Anticoagulants Ineligible for Phase III Trials of Direct Oral Anticoagulants\u3000\u2015 A Retrospective Cohort Study \u2015. Circulation Reports ;advpub https:\/\/doi.org\/10.1253\/circrep.CR-25-0079","DOI":"10.1253\/circrep.CR-25-0079"},{"key":"3269_CR48","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2012883","author":"K Okumura","year":"2020","unstructured":"Okumura K, Akao M, Yoshida T (2020) Low-dose edoxaban in very elderly patients with atrial fibrillation. N Engl J Med. https:\/\/doi.org\/10.1056\/NEJMoa2012883","journal-title":"N Engl J Med"},{"issue":"4","key":"3269_CR49","doi-asserted-by":"publisher","DOI":"10.1161\/jaha.117.007633","volume":"7","author":"BA Steinberg","year":"2018","unstructured":"Steinberg BA, Shrader P, Pieper K et al (2018) Frequency and outcomes of reduced dose non-vitamin K antagonist anticoagulants: results from ORBIT-AF II (the outcomes registry for better informed treatment of atrial fibrillation II). J Am Heart Assoc 7(4):e007633. https:\/\/doi.org\/10.1161\/jaha.117.007633","journal-title":"J Am Heart Assoc"},{"key":"3269_CR50","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.i3189","volume":"353","author":"TB Larsen","year":"2016","unstructured":"Larsen TB, Skjoth F, Nielsen PB, Kjaeldgaard JN, Lip GY (2016) Comparative effectiveness and safety of non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. BMJ 353:i3189. https:\/\/doi.org\/10.1136\/bmj.i3189","journal-title":"BMJ"},{"key":"3269_CR51","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.j510","volume":"356","author":"PB Nielsen","year":"2017","unstructured":"Nielsen PB, Skjoth F, Sogaard M et al (2017) Effectiveness and safety of reduced dose non-vitamin K antagonist oral anticoagulants and warfarin in patients with atrial fibrillation: propensity weighted nationwide cohort study. BMJ 356:j510. https:\/\/doi.org\/10.1136\/bmj.j510","journal-title":"BMJ"}],"container-title":["Journal of Thrombosis and Thrombolysis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-026-03269-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11239-026-03269-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11239-026-03269-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T09:16:25Z","timestamp":1786007785000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11239-026-03269-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,18]]},"references-count":51,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2026,8]]}},"alternative-id":["3269"],"URL":"https:\/\/doi.org\/10.1007\/s11239-026-03269-5","relation":{},"ISSN":["1573-742X"],"issn-type":[{"value":"1573-742X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,18]]},"assertion":[{"value":"26 November 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"11 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Financial: T.A.C.d.V. reports research support from Daiichi Sankyo; personal fees from Bristol Myers Squibb; and financial support for printing his doctoral thesis from Amsterdam University Medical Centers, CardioResearch Rijnstate, MEDCON International\/CVKG.nl, and Daiichi Sankyo Nederland BV. J.R.d.G. is supported by an ERA4Health PERSUADE consortium grant, by the Information Technology for European Advancement (ITEA4) grant, number 21026, as well as the CVON\/Dutch Heart Foundation grant 01-002-2022-0118 for the EmbRACE (Electrophysiological and Molecular Biomarkers in Atrial Fibrillation) project. He received research grant funding through his institution from Atricure Inc., Bayer, Boston Scientific, Daiichi Sankyo, Johnson & Johnson, Medtronic, and Philips. He has also received honoraria and consultancy fees from Atricure Inc., Bayer, Berlin-Chemie, Daiichi Sankyo, Johnson & Johnson, Menarini, Medtronic, Novartis, and Servier. M.E.W.H. received speakers fees from Roche Diagnostics, Bayer, BMS\/Pfizer, Boehringer Ingelheim, Daiichi Sankyo and a research grant of the Dutch Thrombosis Federation. J.J.K., E.M.F., and R.S. are employees of Daiichi Sankyo. LP reports having received fees and honoraria from Daiichi Sankyo, SOTIO and Beckman Coulter. ID reports speaker fees from Daiichi Sankyo and Pfizer. JS has received consultant and\/or speaker fees from Abbott, Bayer, Berlin-Chemie, Biosense Webster, Biotronik, Boehringer-Ingelheim, Boston Scientific, BMS, Daiichi Sankyo, Medscape, Medtronic, Menarini, Pfizer, Saja, Servier, and WebMD. He reports ownership of Swiss EP and CorXL. P.K. receives research support for basic, translational, and clinical research projects from European Union (BigData@Heart, grant agreement EU IMI 116074; AFFECT-AF, grant agreement 84770; MAESTRIA, grant agreement 965286), British Heart Foundation (PG\/17\/30\/32961; PG\/20\/22\/35093; AA\/18\/2\/34218), Leducq Foundation, Medical Research Council (United Kingdom), and German Centre for Cardiovascular Research, from several drug and device companies active in AF, and has received honoraria from several such companies in the past, but not in the last three years. He is an inventor on two patents held by University of Birmingham (Atrial Fibrillation Therapy WO 2015140571, Markers for Atrial Fibrillation WO 2016012783). R.D.C. has received fees, honoraria and\/or research funding from Sanofi-Aventis, Boehringer Ingelheim, Bayer, Bristol Myers Squibb\/Pfizer, Daiichi Sankyo, Novartis, Portola, Roche, Menarini, and Guidotti. Other authors declare no financial interests.Non-financial: T.A.C.d.V is a member of the adjudication committee for the Left Atrial Appendage Exclusion for Prophylactic Stroke Reduction Trial (LeAAPS; NCT05478304), sponsored by AtriCure; the Low International Normalized Ratio to Minimize Bleeding with Mechanical Valves trial (LIMIT; NCT03636295) and the Direct Oral Anticoagulation versus Warfarin after Cardiac Surgery trial (DANCE; NCT04284839), both sponsored by the Population Health Research Institute. He also serves on the Data Safety Committee of the DUTCH Weight Control in Atrial Fibrillation Study (DUTCH-WAIST; NCT06184633), sponsored by Rijnstate Hospital. All other authors report no non-financial interests.Non-Financial:T.A.C.d.V is a member of the adjudication committee for the Left Atrial Appendage Exclusion for Prophylactic Stroke Reduction Trial (LeAAPS; NCT05478304), sponsored by AtriCure; the Low International Normalized Ratio to Minimize Bleeding with Mechanical Valves trial (LIMIT; NCT03636295) and the Direct Oral Anticoagulation versus Warfarin after Cardiac Surgery trial (DANCE; NCT04284839), both sponsored by the Population Health Research Institute. He also serves on the Data Safety Committee of the DUTCH Weight Control in Atrial Fibrillation Study (DUTCH-WAIST; NCT06184633), sponsored by Rijnstate Hospital. All other authors report no non-financial interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All participants provided written informed consent.","order":2,"name":"Ethics","label":"Consent","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"ETNA-AF-Europe is performed in accordance with the Declaration of Helsinki, and its study protocol approvals were provided by competent authorities, and central and local ethics committees for each participating site, in all countries involved.","order":3,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Declarations"}}]}}